Navigation Links
NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
Date:2/8/2011

SANTA CLARA, Calif., Feb. 8, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited to present the results of a key QTinno® performance study at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics (ASCPT), to be held in Dallas, March 3-5, 2011.

The study, entitled "Intelligent Automated ECG Extraction from Continuous 12-Lead Holter Recordings Reduces Measurement Variability in Thorough QT Studies," was completed in collaboration with physician scientists from a global pharmaceutical partner. Continuous 24-hour ECG recordings (Holters) are commonly used in cardiac safety drug studies.  At present, the user visually selects three 10 second ECGs from the recording within 5 minutes of each designated study time point, a labor-intensive approach that is prone to error and variability. NewCardio has developed a novel ECG selection algorithm that evaluates the entire 10-minute window around the designated time point and selects the lowest noise and most stable ECGs in the window. The study chosen for presentation at the ASCPT meeting shows NewCardio's automated ECG selection method yields substantially more accurate and precise data than visual ECG selection.  Moreover, the accuracy gain from automated ECG selection is fully additive to the accuracy gain delivered by QTinno itself.

Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We are pleased to have this opportunity to present our results on automated ECG selection at the annual ASCPT meeting. This is a prestigious and well-attended forum, and gives us an excellent opportunity to share our latest QTinno improvements and innovations with scientists and professionals from academia, drug regulatory bodies, clinical trial service providers, and the pharmaceutical industry. The data we will be presenting demonstrate that NewCardio's novel automated ECG selection algorithm substantially improves data quality in drug safety studies. Pharma sponsors can use our automated ECG selection technology and QTinno to increase study power, thereby reducing the risk of a failed study. Alternatively, the sponsor can reduce the number of subjects in a study without sacrificing study power, which may represent a substantial cost savings. We believe this is a powerful extension of our platform technology, and demonstrates NewCardio's ability to add value to every ECG."  

About QTinno TechnologyNewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.

About the American Society for Clinical Pharmacology and Therapeutics (ASCPT)The American Society for Clinical Pharmacology and Therapeutics (ASCPT) consists of over 2,100 professionals committed to promoting and advancing the science and practice of human pharmacology and therapeutics, and is the largest professional organization serving the discipline of clinical pharmacology.

About NewCardio, Inc.NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG.  NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.  NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.

Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0Investor Contact:Hayden IRJeff Stanlis, Partner(602) 476-1821jeff@haydenir.com
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
2. NewCardios Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
3. NewCardio Announces Financial Results for Its 2010 Third Quarter
4. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
5. NewCardio CEO Increases Equity Position
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
8. NewCardio Announces Master Services Agreement With Dedicated Phase I
9. NewCardio Leadership to Present Two Abstracts at ISCE Conference
10. Vincent W. Renz Joins NewCardio as President
11. NewCardio Announces Positive Results From Third Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):